{
    "title": "Bluebird's $2.8 mln gene therapy becomes most expensive drug after U.S. approval",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11121007/U-S-FDA-approves-bluebird-bios-gene-therapy-rare-blood-disorder.html",
    "date": "2022-08-17",
    "keywords": [
        "treatment",
        "therapy",
        "blood",
        "price",
        "roy",
        "gene",
        "approval",
        "zynteglo",
        "bluebird",
        "payment",
        "transfusion",
        "food",
        "drug",
        "administration",
        "disorder",
        "drugmaker",
        "record",
        "companys",
        "betathalassemia",
        "oxygen",
        "shortage",
        "body",
        "heart",
        "resistance",
        "insurance",
        "coverage",
        "instance",
        "novartis",
        "work",
        "zolgensma",
        "onetime",
        "need",
        "term",
        "cost",
        "lifetime",
        "chief",
        "officer",
        "tom",
        "value",
        "option",
        "patient",
        "independence",
        "klima",
        "fda",
        "risk",
        "cancer",
        "process",
        "quarter",
        "revenue",
        "cycle",
        "average",
        "cell",
        "collection",
        "reporting",
        "bengaluru",
        "editing",
        "aditya",
        "soni"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}